Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be at least 18 years old.~* Patient must be diagnosed with depression and have had previous episodes of depression.~* Patient must sign informed consent.~Exclusion Criteria:~* Female and pregnant or breastfeeding.~* History of bipolar disorder, schizophrenia, or other psychotic disorders.~* Suffer from a serious medical illness (other than depression) or abnormal laboratory result that would require a change in medication, intervention, or hospitalization.~* Have been treated with a medication called monoamine oxidase inhibitor (MAOI) within 14 days of the start of the study, or potential need to use a MAOI within 5 days of finishing the study.~* Have taken an antidepressant called fluoxetine within 30 days of the start of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks
- B (Type: PLACEBO_COMPARATOR): duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).